Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2024-04-04 | Dr. Mulligan has served on the Board since May 2022. Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. Dr. Mulligan also currently serves as Executive Vice Chairman of the Board of Sana Biotechnology, Inc. a public biotechnology company. He previously served as a director of Biogen Inc., a public biotechnology company, from June 2009 to June 2023. Prior to Harvard, Dr. Mulligan was a professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and Chief Scientific Officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was a founding partner of Sarissa Capital Management LP from 2013 to 2016 and from March 2017 to October 2018 served as Portfolio Manager at Icahn Capital LP. He was named a MacArthur Foundation Fellow in 1981. Stock Ownership: 36,704 Common Shares — $ 337,677; 29,205 RSUs (comprised of 0 vested RSUs — $0, and 29,205 unvested RSUs — $268,686). Total Equity Value at Risk: $337,677 representing 68% of the Company’s current aggregate amount of $500,000 required under the share ownership guidelines for non-employee Directors and 338% of the annual Board retainer. Dr. Mulligan has until May 10, 2027 to achieve the expected minimum equity ownership under such share ownership guidelines. 2023 Meeting Attendance: Board: 8/8; Nominating & Corporate Governance Committee: 6/6; Science & Technology Committee: 4/4. The Board has determined that Dr. Mulligan’s extensive experience in the biotechnology and life sciences industries and international reputation in academia qualifies him to serve as a member of the Board and the committees on which he serves. |
| 2025-04-02 | Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School. ... Committees: Nominating & Corporate Governance Committee, Science & Technology Committee (Chair). ... Director Compensation Table shows total compensation of $382,500. |
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-30 | Richard C. Mulligan, Ph.D. Age: 59 Director since: 2009 Committee Memberships: Science and Technology |
| 2015-04-30 | Richard C. Mulligan, Ph.D. Age: 60 Committee Memberships: Compensation and Management Development, Science and Technology (Chair) Dr. Mulligan has served as one of our directors since 2009. |
| 2016-04-15 | Dr. Mulligan, 61, has served as one of our directors since 2009. Dr. Mulligan is a founding partner of Sarissa Capital Management LP. Sarissa Capital focuses on improving the strategies of companies to better provide stockholder value. In 2013, Dr. Mulligan became the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative since 1996. Prior to that, he was Professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research, and the Chief Scientific Officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was named a MacArthur Foundation Fellow in 1981. Dr. Mulligan has scientific expertise in the areas of molecular biology, genetics, gene therapy, and biotechnology, as well as extensive experience within the healthcare industry, including overseeing the operations and research and development of healthcare companies. Biogen Committee Memberships: Science and Technology (Chair), Compensation and Management Development. 2015 Director Compensation: $401,508. |
| 2017-04-26 | Dr. Mulligan, 62, has served as one of our directors since 2009. He is currently a Portfolio Manager at Icahn Capital LP and, since 2013, the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School. Dr. Mulligan has scientific expertise in the areas of molecular biology, genetics, gene therapy, and biotechnology, as well as extensive experience within the healthcare industry, including overseeing the operations and research and development of healthcare companies. Biogen Committee Memberships: Science and Technology (Chair), Compensation and Management Development. 2016 Director Compensation: $445,920. |
| 2018-04-27 | Dr. Mulligan, 63, has served as one of our directors since 2009. Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. He also currently serves as a Portfolio Manager at Icahn Capital LP, a position held since March 2017. Prior to Harvard, Dr. Mulligan was a Professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and the Chief Scientific Officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was a founding partner of Sarissa Capital Management LP, a registered investment advisor, from 2013 to 2016. Dr. Mulligan was named a MacArthur Foundation Fellow in 1981. Dr. Mulligan has scientific expertise in the areas of molecular biology, genetics, gene therapy and biotechnology, as well as extensive experience within the healthcare industry, including overseeing the operations and research and development of healthcare companies. Biogen Committee Memberships: Science and Technology (Chair), Compensation and Management Development. 2017 Director Compensation: $420,479. |
| 2019-04-30 | Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. He also currently serves as Executive Vice Chairman of the Board of Sana Biotechnology, a private biotechnology company. From March 2017 to October 2018 Dr. Mulligan served as a Portfolio Manager at Icahn Capital LP. Prior to that, Dr. Mulligan was a founding partner of Sarissa Capital Management LP, a registered investment advisor, from 2013 to 2016. Prior to Harvard, Dr. Mulligan was a Professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and the Chief Scientific Officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was named a MacArthur Foundation Fellow in 1981. |
| 2020-04-20 | Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School... Biogen Board Committee: Compensation and Management Development... 2019 Director Compensation: Richard C. Mulligan total $401,393. |
| 2021-04-23 | Dr. Mulligan is Mallinckrodt Professor of Genetics, Emeritus, Harvard Medical School... Biogen Board Committee: Compensation and Management Development... 2020 Director Compensation: Richard C. Mulligan total $409,314. |
| 2022-04-29 | Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, Harvard Medical School... Biogen Board Committee: Compensation and Management Development... 2021 Director Compensation: Richard C. Mulligan Fees Earned or Paid in Cash $140,000, Stock Awards $270,413, Total $410,413. |
| 2023-04-28 | Richard C. Mulligan, Ph.D. Director Since: 2009 Age: 68 Biogen Board Committee: Compensation and Management Development 2022 Director Compensation Table: Richard C. Mulligan Fees Earned or Paid in Cash: $140,000 Stock Awards: $270,246 Total: $410,246 |
Data sourced from SEC filings. Last updated: 2026-02-03